





# Healthcare worker infections with the SARS-CoV-2 virus following the inception of an adult COVID-19 intensive care unit

Allanah Baukes<sup>A</sup> (RN, BHealthSci, CritCareDip, Acting Nurse Unit Manager), Alison Brannelly<sup>A</sup> (RN, BA, ICUCert, Clinical Nurse Educator), Winston Cheung<sup>A,B,C,\*</sup> (MBChB, FCICM, FRACP, Staff Specialist Intensivist, Clinical Associate Professor), Rosalba Cross<sup>A</sup> (MBBS, FCICM, Staff Specialist Intensivist), Thomas Gottlieb<sup>A,B</sup> (MBBS, FRACP, FRCPA, Staff Specialist Microbiology and Infectious Diseases, Clinical Associate Professor), Timothy Gray<sup>A,B</sup> (MBBS, FRACP, FRCPA, Staff Specialist Microbiology and Infectious Diseases, Clinical Senior Lecturer), Karina Griffiths<sup>D</sup> (BN, GradCertCritCare, Senior Nurse Educator), Rhiannon Hunt<sup>A</sup> (RN, MIntCareNurs, Nurse Unit Manager), Mark Kol<sup>A,B</sup> (BA, MBBS(Hons), FRACP, FCICM, ICU Director, Clinical Senior Lecturer), Ying Li<sup>A</sup> (RN, MIntCareNurs, Clinical Nurse Educator), Genevieve Mckew<sup>A,B</sup> (MBBS, FRACP, FRCPA, Staff Specialist Microbiology and Infectious Diseases, Clinical Lecturer), Anne Mendes<sup>A</sup> (BA, MA, ICU Secretary), Asim Shah<sup>A,B</sup> (MBChB, MSc, FACEM, FCICM, FRCEM, Staff Specialist Intensivist, Clinical Senior Lecturer), Katina Skylas<sup>A</sup> (RN, MClinNurs(CritCare), Clinical Nurse Consultant Intensive Care), Gemma Smith<sup>A</sup> (RN, MClinNurs, GradCertInfPrevControl, Acting Clinical Nurse Consultant Infection Prevention and Control), Atul Wagh<sup>A,B</sup> (MBBS, MD, DNB, EDIC, FCICM, Staff Specialist Intensivist, Clinical Lecturer) and Helen Wong<sup>A</sup> (RN, Data Manager)

For full list of author affiliations and declarations see end of paper

# \*Correspondence to:

Winston Cheung
Concord Repatriation General Hospital,
Hospital Road, Concord, Sydney,
NSW 2139, Australia
Email: winston.cheung@health.nsw.gov.au

Received: 8 October 2021 Accepted: 11 October 2021 Published: 28 March 2022

#### Cite this:

Baukes A et al. (2022) Australian Health Review **46**(2), 251–253. doi:10.1071/AH21324

© 2022 The Author(s) (or their employer(s)). Published by CSIRO Publishing on behalf of AHHA. This is an open access article distributed under the Creative Commons Attribution 4.0 International License (CC BY).

**OPEN ACCESS** 

In Australia, there have been outbreaks of coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus in healthcare workers (HCWs), with an estimated 70% of infections acquired at work, in the prevaccination era. $^{1,2}$ 

In July 2021, a 'third wave' of SARS-CoV-2 infections began in New South Wales (NSW), Australia, with 91 SARS-CoV-2 infections recorded in HCWs by 22 September.<sup>3</sup> To manage the outbreak, our hospital opened an additional intensive care unit (ICU), dedicated to managing adult patients with COVID-19. Due to limited robust data on strategies to prevent infections in HCWs, this cohort study was conducted to determine whether the new COVID-19 ICU could be operationalised using infection–prevention strategies that would result in zero ICU staff infections from SARS-CoV-2. <sup>4-6</sup>

During a 6-week period from 9 August to 19 September 2021, we examined data from all patients admitted to the new COVID-19 ICU and ICU staff who tested positive for SARS-CoV-2. The hospital Human Research Ethics Committee had no ethical concerns.

The hospital had 590 beds and a single 13-bed general ICU. The new 11-bed COVID-19 ICU was repurposed from an existing ward adjacent to the existing ICU.

The SARS-CoV-2 infection-prevention strategies used for the new ICU are detailed in Box 1

During the study period, the community prevalence of SARS-CoV-2 ranged between 61.2 and 227.0 per 100 000 population.  $^{7,8}$ 

There were 75 patients who were admitted to the COVID-19 ICU. The mean age was 54 years and 76% were male. The mean acute physiology and chronic health evaluation (APACHE) II score was 11 (s.d. 6). The proportion of patients receiving invasive ventilation, non-invasive ventilation and high-flow nasal oxygenation were 31%, 26% and 75% respectively.

Approximately 214 nursing, medical and allied health staff spent an estimated 13 900 h in the COVID-19 ICU. There were zero SARS-CoV-2 infections (95% confidence interval 0–1.7%) recorded in staff working in the COVID-19 ICU during the study period.

Our study demonstrated that no ICU staff contracted SARS-CoV-2 infections during the first 6 weeks of operation of a new COVID-19 ICU. We postulate that the elements that

Allanah Baukes et al.

Australian Health Review

Box I. SARS-CoV-2 transmission prevention strategies in the new COVID-19 ICU.

## **Environment**

Single patient rooms with negative flow ventilation (no anterooms)

Doors to patient rooms alarm if left open

ICU entrance with change rooms, showers and separate area to put on and remove personal protective equipment (PPE)

Separate staff office and toilet area

Three separate staff dining areas with one person per 4 m<sup>2</sup> limit

## Patient factors

Observation of patient by staff from outside of patient room where possible

Surgical face mask worn by patients over high flow nasal cannula if staff present in patient room

Non-vented circuit used for non-invasive ventilation where possible

Visitation ban

## Patient waste disposal

Disposable urine containers and disposable bed pans Absorbent polymer powder used to solidify liquids to aid disposal

# Staff vaccination

Mandatory ICU staff vaccination (two doses of BNT162b2 (BioNTech/Pfizer) vaccine)

#### Staff numbers

Nurse-to-patient ratio one-to-one, or one-to-two if both patients are stable on low levels of support

Nurse manager during daytime

Nursing team leader for each shift

Ward secretary for restocking and administrative services during daytime

Cleaners (two) during daytime

# Staff personal protective equipment

On entering ICU – wear surgical scrubs, disposable N95 mask, cleanable eyewear, and wipeable footwear

Before entering patient room – wear additional disposable fluid repellent gown, disposable long cuff nitrile gloves, disposable balaclava head and neck covering, and disposable face shield

Before exiting patient room – remove disposable gown, gloves, head and neck covering and face shield

After exiting patient room - clean eyewear, discard and replace disposable N95 mask

Endotracheal intubation – same as PPE for entering patient room

Sterile procedures – same as PPE for entering patient room except sterile gown and gloves

## Staff quantitative mask fit testing

Mandatory staff mask fit testing (TSI PortaCount Pro + Respirator Fit Tester 8038 and FitPro + 3.2.0 (TSI, USA))

#### Staff education and administration

Training and monitoring of staff by nurse educators, clinical nurse consultant, and special projects team during daytime

Mandatory competency assessment for putting on and removing PPE

Review and incident management of observed PPE breaches Signs instructing how to put on and remove PPE and when to perform hand hygiene placed inside and outside all patient rooms and at all PPE stations

Social distancing, minimisation of crowding

Restrictions on non-essential face-to-face meetings Furloughing staff at risk from community or occupational exposure

# Staff surveillance testing

Mandatory surveillance testing twice a week if staff reside in a community with a high prevalence of SARS-CoV-2 infection (multi-panel polymerase chain reaction (PCR) test using SARS-CoV-2, influenza and RSV panel (AusDiagnostics Pty Ltd))

Mandatory testing if staff have COVID-19 symptoms Voluntary surveillance testing, otherwise up to twice a week

were likely to have made this possible were preventing environmental contamination to the common areas of the ICU, enhanced PPE when in direct patient contact, and meticulous education of infection prevention procedures.

There are currently no other publications specifically demonstrating the design and operational specifications for a COVID-19 ICU that completely negate workplace SARS-CoV-2 infection transmission.<sup>9</sup>

Limitations to our study include being conducted in a single centre and a short observation period. Surveillance testing for SARS-CoV-2 infection in HCWs was not mandatory, except in HCWs from community areas with high prevalence, so it is possible that some HCWs may have had undiagnosed asymptomatic infection.

Some of the infection–prevention procedures could be regarded as overcautious and may have resource implications where PPE supply is limited. It is unknown whether using less PPE could also negate workplace SARS-CoV-2 transmission in ICU HCWs.

www.publish.csiro.au/ah

Australian Health Review

In conclusion, our study demonstrates that it is possible to operationalise a COVID-19 ICU in a way that prevents workplace SARS-CoV-2 transmission to staff.

## **References**

- 1 Buising KL, Williamson D, Cowie BC, MacLachlan J, Orr E, MacIsaac C, Williams E, Bond K, Muhi S, McCarthy J, Maier AB, Irving L, Heinjus D, Kelly C, Marshall C. A hospital-wide response to multiple outbreaks of COVID-19 in health care workers: lessons learned from the field. *Med J Aust* 2021; 214: 101–104.e.1. doi:10.5694/mja2.50850
- 2 Smith P. Covid-19 in Australia: most infected health workers in Victoria's second wave acquired virus at work. *BMJ* 2020; 370: m3350. doi:10.1136/bmj.m3350
- 3 NSW Government. COVID-19 risk monitoring dashboard healthcare settings. 22 September 2021. Available at https://aci.health.nsw. gov.au/covid-19/critical-intelligence-unit/dashboard [verified 24 September 2021].
- 4 World Health Organization. Infection prevention and control during health care when coronavirus disease (COVID-19) is suspected or

- confirmed: interim guidance, 12 July 2021. 2021. Available at https://apps.who.int/iris/handle/10665/342620 [verified 8 September 2021].
- 5 Centers for Disease Control and Prevention. Interim infection prevention and control recommendations for healthcare personnel during the coronavirus disease (COVID-19) pandemic. 2021. Available at https://www.cdc.gov/coronavirus/2019-ncov/hcp/infection-control-recommendations.html [verified 8 September 2021].
- 6 Gross JV, Mohren J, Erren TC. COVID-19 and healthcare workers: a rapid systematic review into risks and preventive measures. *BMJ Open* 2021; 11: e042270. doi:10.1136/bmjopen-2020-042270
- 7 Australian Government, Department of Health. Coronavirus (COVID-19) case numbers and statistics. 2021. Available at https://www.health. gov.au/news/health-alerts/novel-coronavirus-2019-ncov-health-alert/coronavirus-covid-19-case-numbers-and-statistics#covid19-summary-statistics [verified 15 September 2021].
- 8 Australian Bureau of Statistics. National, state and territory population. 2021. Available at <a href="https://www.abs.gov.au/statistics/people/population/national-state-and-territory-population/dec-2020">https://www.abs.gov.au/statistics/people/population/national-state-and-territory-population/dec-2020</a> [verified 15 September 2021].
- 9 Ingram C, Downey V, Roe M. COVID-19 prevention and control measures in workplace settings: a rapid review and meta-analysis. *In J Environ Res Public Health* 2021; 18: 7847. doi:10.3390//jerph18157847

Data availability. The data that support this study cannot be publicly shared due to ethical or privacy reasons and may be shared upon reasonable request to the corresponding author.

Conflicts of interest. Winston Cheung declares that he has convened educational events that have received financial assistance from 3M, AB Applied Biosystems, AB Sciex, Abbott Medical Optics, Actelion, Advanz Pharma, Alcon, Amgen, Aquatic Solutions, Aspen, Avant Mutual, Bayer Healthcare, BD, Bioline, Boehringer-Ingelheim, B Braun, Celgene, Charcot-Marie-Tooth Association of Australia, CSL Biotherapies, Fresenius Kabi, Glaxo Smith Kline, Genzyme, Immune System Therapeutics, Infusion 360, Invitrogen, Ipsen, Janssen-Cilag, Johnson and Johnson, Leica Microsystems, Life Technologies, Lilly, Macrogen, Medtronic, MACS Miltenyi Biotec, Merck Sharpe and Dohme, National Home Doctor Service, Novartis, Pfizer, PPS Mutual, Roche, Sanofi-Aventis, Schering Plough, Servier, and Wyeth. None of the other authors have any relevant conflicts of interest to declare.

Declaration of funding. This research did not receive any specific funding.

#### **Author affiliations**

<sup>A</sup>Concord Repatriation General Hospital, Hospital Road, Concord, Sydney, NSW 2139, Australia.

<sup>B</sup>Sydney School of Medicine – Concord, University of Sydney, Hospital Road, Concord, NSW 2139, Australia.

<sup>C</sup>The George Institute for Global Health – Australia, Level 5, 1 King Street, Newtown, NSW 2050, Australia.

<sup>D</sup>Centre for Education and Workforce Development, Sydney Local Health District, Rozelle Campus, Building 301, Callan Park, Balmain Road, Lilyfield, NSW 2039, Australia.